During the last session, Compass Therapeutics Inc (NASDAQ:CMPX)’s traded shares were 1.26 million, with the beta value of the company hitting 0.96. At the end of the trading day, the stock’s price was $3.45, reflecting an intraday loss of -8.00% or -$0.3. The 52-week high for the CMPX share is $4.08, that puts it down -18.26 from that peak though still a striking 77.97% gain since the share price plummeted to a 52-week low of $0.76. The company’s market capitalization is $474.68M, and the average trade volume was 1.32 million shares over the past three months.
Compass Therapeutics Inc (CMPX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.38. CMPX has a Sell rating from 1 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Compass Therapeutics Inc (CMPX) registered a -8.00% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.00% in intraday trading to $3.45, hitting a weekly high. The stock’s 5-day price performance is -1.43%, and it has moved by 72.50% in 30 days. Based on these gigs, the overall price performance for the year is 112.96%.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 31.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, CMPX is trading at a discount of -44.93% off the target high and -44.93% off the low.
Compass Therapeutics Inc (CMPX) estimates and forecasts
Statistics show that Compass Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Compass Therapeutics Inc (CMPX) shares have gone up 187.50% during the last six months, with a year-to-date growth rate less than the industry average at -6.06% against 15.30.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.88%. While earnings are projected to return -5.68% in 2025, the next five years will return -9.03% per annum.
CMPX Dividends
Compass Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 11.13 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 8.0893% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.13 million.
